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A Common Functional Regulatory Variant
at a Type 2 Diabetes Locus Upregulates
ARAP1 Expression in the Pancreatic Beta Cell
Jennifer R. Kulzer,1 Michael L. Stitzel,2,3 Mario A. Morken,2 Jeroen R. Huyghe,4 Christian Fuchsberger,4
Johanna Kuusisto,5 Markku Laakso,5 Michael Boehnke,4 Francis S. Collins,2 and Karen L. Mohlke1,*
Genome-wide association studies (GWASs) have identified more than 70 loci associated with type 2 diabetes (T2D), but for most, the
underlying causal variants, associated genes, and functional mechanisms remain unknown. At a T2D- and fasting-proinsulin-associated
locus on 11q13.4, we have identified a functional regulatory DNA variant, a candidate target gene, and a plausible underlying molecular
mechanism. Fine mapping, conditional analyses, and exome array genotyping in 8,635 individuals from the Metabolic Syndrome in
Men study confirmed a single major association signal between fasting proinsulin and noncoding variants (p ¼ 7.4 3 1050). Measure-
ment of allele-specific mRNA levels in human pancreatic islet samples heterozygous for rs11603334 showed that the T2D-risk and pro-
insulin-decreasing allele (C) is associated with increased ARAP1 expression (p < 0.02). We evaluated four candidate functional SNPs for
allelic effects on transcriptional activity by performing reporter assays in rodent pancreatic beta cell lines. The C allele of rs11603334,
located near one of the ARAP1 promoters, exhibited 2-fold higher transcriptional activity than did the T allele (p < 0.0001); three other
candidate SNPs showed no allelic differences. Electrophoretic mobility shift assays demonstrated decreased binding of pancreatic beta
cell transcriptional regulators PAX6 and PAX4 to the rs11603334 C allele. Collectively, these data suggest that the T2D-risk allele of
rs11603334 could abrogate binding of a complex containing PAX6 and PAX4 and thus lead to increased promoter activity and
ARAP1 expression in human pancreatic islets. This work suggests that increased ARAP1 expression might contribute to T2D suscepti-
bility at this GWAS locus.Introduction
Genome-wide association studies (GWASs) have identified
more than 70 loci associated with type 2 diabetes (T2D
[MIM 125853])1–9 and ten loci associated with fasting pro-
insulin levels.10,11 A 11q13.4 locus near ARAP1 (MIM
606646), PDE2A (MIM 602658), STARD10, ATG16L2, and
FCHSD2 is strongly associated with T2D (rs1552224, p ¼
1.4 3 1022),1 fasting proinsulin (rs11603334, p ¼ 3.2 3
10102),10 and 32,33-split proinsulin (rs11603334, p ¼
1.2 3 1025).10 This locus is also nominally associated
with the insulinogenic index (rs1552224, p ¼ 2 3 106)
and both insulin (p ¼ 0.001) and glucose (p ¼ 2 3 105)
levels at 30 min during an oral glucose tolerance test.12
The clustering of multiple phenotypic associations related
to proinsulin processing and insulin secretory response
during an oral glucose challenge suggests that the affected
target gene(s) might play a role in pancreatic beta cell func-
tion. Currently, the functional DNA variant(s), the affected
gene(s), and the underlying molecular genetic mecha-
nism(s) contributing to these associations are unknown.
SNPs rs1552224 and rs11603334 are in perfect link-
age disequilibrium (LD) with each other (r2 ¼ 1, 1000
Genomes European ancestry [EUR]) and are located
within the first exon and 50 UTR of ARAP1 RefSeq isoforms
NM_015242.4 and NM_001135190.1 (rs1552224, þ305 nt
from the transcription start site [TSS]; rs11603334,þ418 nt
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on chromosome 11. A third ARAP1 RefSeq isoform,
NM_001040118.2, is expressed from an alternative pro-
moter and TSS located at 72.14 Mb. We designate the pro-
moter at 72.11MbasP1 and thepromoter at 72.14MbasP2.
We hypothesized that functional variant(s) at this locus
are in high LD (r2R 0.8) with rs1552224 and rs11603334.
None of the variants in high LDwith these SNPs are within
gene coding regions where they could alter protein func-
tion, suggesting that functional common SNP(s) at this
locus might influence gene regulation. Genes within
the LD region containing rs1552224 and rs11603334
have reported expression in human pancreas, islets,
and flow-sorted beta cells;1 however, islet expression of
ATG16L2, FCHSD2, and PDE2A might not be above back-
ground.13–15 None of these genes have been demonstrated
to play roles in insulin processing or secretion. ARAP1 acti-
vates Arf and Rho GTPases, which regulate membrane traf-
ficking and actin cytoskeleton reorganization.16 STARD10
binds and transfers membrane phospholipids.17 PDE2A
is a cyclic nucleotide phosphodiesterase that degrades
second messengers cGMP and cAMP.18 ATG16L2 shares
sequence homology with ATG16, a protein required for
autophagy in yeast.19 FCHSD2 is named for its FCH and
SH3 protein domains.20
Here, we show data supporting rs11603334 as a
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fine-mapping data and conditional analyses support a sin-
gle association signal. We demonstrate that the T2D-risk
allele (C) of rs11603334 is associated with increased
ARAP1 transcript levels in primary human pancreatic is-
lets, disrupts binding of a protein complex containing
transcriptional regulators, and increases transcriptional ac-
tivity at the ARAP1 P1 promoter. These data suggest that
increased ARAP1 P1 promoter activity and ARAP1 expres-
sion might be molecular consequences of the T2D-associ-
ated variants in this region.Material and Methods
Study Population and Phenotypes
In the proinsulin association analyses, we included 8,635 Finnish
men without diabetes and not taking diabetes medication (mean
age ¼ 57.2 years [range ¼ 45–74 years]; mean body mass index
[BMI] ¼ 26.8 kg/m2 [range ¼ 16.2–51.6 kg/m2]; fasting plasma
glucose levels < 7 mmol/l; and plasma glucose levels after 2 hr
oral glucose tolerance test < 11.1 mmol/l) from the population-
based Metabolic Syndrome in Men (METSIM) study.21 Fasting
plasma-specific proinsulin (Human Proinsulin RIA Kit, Linco
Research; no cross-reaction with insulin or C-peptide) and fasting
insulin (ADVIA Centaur Insulin IRI, 02230141, Siemens Medical
Solutions Diagnostics; minimal cross-reaction with proinsulin or
C-peptide) were measured by immunoassay. For the T2D associa-
tion analyses, 1,389 T2D cases and 5,748 normoglycemic controls
were included. The study was approved by the ethics committee of
the University of Kuopio and Kuopio University Hospital, and
informed consent was obtained from all study participants.Genotyping
Samples were genotyped with the Illumina HumanOmniExpress
BeadChip. In sum, 681,789 autosomal SNPs passed quality control
(Hardy-Weinberg equilibrium [HWE] p R 1 3 106 in the total
sample; call frequencyR 0.97). The same samples were previously
genotyped with the Illumina HumanExome BeadChip,11 which
focuses on protein-altering variants selected from >12,000 exome
and genome sequences.Imputation and Reference Panel
We used a two-step imputation strategy wherein samples were pre-
phased with ShapeIT version 222 before genotypes were imputed
with Minimac.23 To increase imputation quality, we used 5,474
haplotypes from the 2,737 central-northern European samples
sequenced within the Genetics of Type 2 Diabetes (GoT2D) study
as a reference panel (C.F., J. Flannick, K. Gaulton, H. Kang, and the
GoT2D Consortium, unpublished data).Fine-Mapping and Conditional Analysis
Assuming an additive genetic model and adjusting for age, BMI,
and log-transformed fasting plasma insulin, we tested SNP associa-
tions with log-transformed fasting plasma proinsulin levels by
using a linear mixed model with an empirical kinship matrix to
account for relatedness as implemented in EMMAX.24We analyzed
both raw residuals and rank-based inverse-normal-transformed
residuals to assess robustness of rare-variant associations with out-
liers. Genotyped variantswithminor allele countR 5 (minor allele
frequency [MAF] ~ 0.03%) andHWEpR13106 and imputedvar-The Americiants with imputation quality score R2 > 0.3 and MAF R 0.03%
were included in the analyses. To identify additional independent
signals in the region, we performed conditional analyses on previ-
ously reported lead SNP rs11603334 or on our fine-mapped lead
SNP rs7109575 by using allele count (genotyped variants) or allelic
dosage (imputed variants) as a covariate in themodel. SNP associa-
tions with T2D were tested similarly but with adjustment for age
only. Kang et al.24 describe and motivate the use of a linear mixed
model for analysis of a binary outcome.Allelic Expression Imbalance
Human islets from nondiabetic organ donors were obtained from
the National Disease Research Interchange and the Islet Cell
Resource Center Integrated Islet Distribution Program. DNA and
RNA were obtained from 87 primary human pancreatic islet sam-
ples with the use of the PureGene (DNA) or RNAeasy (RNA) kits
(QIAGEN). Reverse transcription of the RNA was performed with
the Superscript III First-Strand Synthesis System (Life Technolo-
gies). Common, transcribed SNPs (MAF R 0.1) with the highest
LD values with previously reported lead SNPs rs11603334
and rs1552224 were selected for testing allelic expression of
ARAP1, STARD10, PDE2A, and FCHSD2. LD plots including the
transcribed SNPs were created with the use of the HapMap
Genome Browser (Figure S1, available online).25 High-quality
genomic DNA (gDNA) and mRNAwere available for five islet sam-
ples heterozygous for rs11603334 and rs1552224; one additional
high-quality heterozygous sample each was available for mRNA
only or gDNA only. For each transcribed SNP, the relative propor-
tions of each allele comprising the gDNA and cDNA were quanti-
fied with Sequenom iPLEX MALDI-TOF mass-spectrometry-based
genotyping (Sequenom). Primers were designed with MassARRAY
(Sequenom) (Table S1). We designed primers within a single exon
to avoid amplicon size differences between gDNA and cDNA,
except for rs2291289, which is located near an exon-intron
boundary. To control for assay variation, we analyzed the propor-
tions of each SNP allele measured in the cDNA relative to measure-
ments taken in the gDNA. Data are reported as the percentage of
total gDNA or cDNA containing a given transcribed SNP allele.
The statistical significance of the differences in allelic representa-
tion was determined on the basis of LD scenarios as previously
described.26 In brief, two-sided t tests were used when the tran-
scribed SNP and lead SNPs were in perfect LD (D0 ¼ 1.0, r2 ¼ 1.0)
or when the transcribed SNP and lead SNPs were in intermediate
LD with low pairwise correlation (D0 z 1.0, r2 < 0.2). For all
t tests, F tests were first used for determining equal or unequal vari-
ance. Nonparametric Wilcoxon pairwise tests were used instead of
t tests when gDNA or cDNAmeasurement data were not normally
distributed. One-sided F tests were used when the transcribed SNP
and lead SNPs were in low LD (D0 < 0.2, r2 < 0.2).Regulatory Variant Selection
All known variants in high LD (r2 R 0.8, EUR) with rs11603334
and rs1552224 were identified with the use of Phase 1 data
from the 1000 Genomes Project.27 Variants were prioritized on
the basis of location relative to regions of potential regulatory
function, as indicated by the following: open chromatin in
primary human pancreatic islets detected by FAIRE28 and DNase
hypersensitivity,29 accessible chromatin in primary human
pancreatic islets detected by chromatin immunoprecipitation
sequencing (ChIP-seq) of active histone H3 lysine methylation
or acetylation modifications (H3K4me3, H3K4me1, and H3K9ac)an Journal of Human Genetics 94, 186–197, February 6, 2014 187
as reported in the Human Epigenome Atlas,30 and transcription
factor binding in ENCODE tissues or cell lines detected by
ChIP-seq.31Cell Culture
The MIN6 mouse insulinoma beta cell line32 was grown in
Dulbecco’s modified Eagle’s medium (Sigma) supplemented
with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, and
100 mM 2-mercaptoethanol. The INS-1-derived 832/13 rat insuli-
noma beta cell line33 (a gift from C.B. Newgard, Duke University)
was grown in RPMI 1640 culture medium (Corning Cellgro) sup-
plemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyru-
vate, 10 mM HEPES, and 0.05 mM 2-mercaptoethanol. Both lines
were maintained at 37C and 5% CO2. One day prior to transfec-
tion, MIN6 cells were seeded at a density of 200,000 cells per well
on 24-well plates. 832/13 cells were seeded at a density of 300,000
cells per well on 24-well plates or 150,000 cells per well on 48-well
plates.Dual Luciferase Transcriptional Reporter Assay
Genomic regions including variant positions were PCR amplified
from human gDNA with 5 PRIME Mastermix (5 PRIME) or the
Expand High Fidelity PCR System (Roche) with the primers listed
in Table S2. Amplified DNA was subcloned with restriction
enzymes XhoI, KpnI, and/or NheI and T4 DNA Ligase (New
England Biolabs) into the multiple cloning site upstream of the
firefly luciferase gene in the pGL4.10 promoterless vector
(Promega). Site-directed mutagenesis was performed with the
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) and
the primers listed in Table S2. For each construct, two to ten
independent clones were selected. The fidelity and genotype of
each gDNA construct were verified by sequencing. Equal
amounts, between 600 and 800 ng, of each gDNA construct or
empty pGL4.10 promoterless vector were cotransfected with
80 ng of Renilla luciferase vector into duplicate wells of MIN6
or 832/13 cells with Lipofectamine 2000 (Life Technologies).
Transfected cells were incubated at 37C and 5% CO2 overnight,
and the transfection media were replaced with fresh culture me-
dia after 24 hr. Forty-eight hours posttransfection, cell lysates
were collected and assayed for luciferase activity with the
Dual-Luciferase Reporter Assay System (Promega). We normalized
firefly luciferase activity to that of Renilla luciferase to control
for differences in transfection efficiency. Normalized data are re-
ported as the fold change (5SD) in activity relative to that of
the empty pGL4.10 promoterless vector control. Two-sided Stu-
dent’s t tests were used for comparing luciferase activity between
genotypes or haplotypes. F tests were used for determining equal
or unequal variance. Two-way ANOVA was used for simultaneous
comparisons of haplotypes resulting from two independently
tested SNPs.
Electrophoretic Mobility Shift Assay and
Transcription Factor Prediction
Four sets of complementary 21-mer oligonucleotides centered on
rs11603334 (C/T) or rs1552224 (T/G) were generated; each con-
tained either of the two alternate alleles, both with and without
biotin end labeling (Integrated DNA Technologies). We annealed
each set to create double-stranded oligonucleotides by incubating
50 pmol of each single-stranded oligonucleotide in buffer contain-
ing 10 mM Tris, 1 mM EDTA, and 50 mM NaCl at 95C for 5 min
and then gradually cooled them to 4C. Double-stranded oligonu-188 The American Journal of Human Genetics 94, 186–197, Februarycleotide sequences are specified in Table S3. Nuclear protein lysates
were extracted from MIN6 and 832/13 cell pellets with NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific),
and protein concentrations were determined with the Pierce BCA
Protein Assay (Thermo Scientific). Electrophoretic mobility shift
assays (EMSAs) were carried out with the LightShift Chemilumi-
nescent EMSA Kit (Thermo Scientific) according to the manufac-
turer’s instructions. Each protein-DNA binding reaction contained
13 binding buffer, 1 mg poly(dIdC), 4 mg nuclear protein lysates,
and 100 fmol biotin-labeled double-stranded oligonucleotide
in 20 ml total reaction volume. For reactions demonstrating DNA
competition, 60-fold excess unlabeled double-stranded oligonu-
cleotide was preincubated with nuclear protein lysates in the
reaction mixture for 20 min before the addition of biotin-labeled
oligonucleotide. For EMSA reactionswith supershift, 4 mg antibody
was added to the final reactionmixture and the samples were incu-
bated for an additional 30 min. We used JASPAR,34 TRANSFAC,35
CONSITE,36 PWMSCAN,37 and Tfsitescan38 to computationally
predict transcription factors that might differentially bind at
rs11603334 by contrasting the predictions and/or scores generated
for each SNP allele. Transcription factor ChIP-seq data for the
region overlapping rs11603334 were obtained from the ENCODE
project.31 Antibody to PAX6 (PRB-278P) was purchased fromCova-
nce. Antibodies to PAX4 (M-45X, sc-98942X) and AP-2b (H-87X,
sc-8976X) were purchased from Santa Cruz Biotechnology. Anti-
bodies to HIF1a (MA1-516) and HIF1b (MA1-515) were purchased
fromThermo Scientific. Additional antibodies to the following fac-
tors were also purchased and tested for supershift: YY1 (39071,
39345), Active Motif; NFIC (ab86570), Abcam; and AP-2a (C-18,
sc-184X), YY1 (C-20, sc-281X; H-414, sc-1703X), MAX (C-124,
sc-765X), p53 (DO-1, sc-126X), OCT3/4 (C-10, sc-5279X), SP1 (E-
3, sc-17824X), USF-1 (C-20, sc-229X), EGR-1 (C-19, sc-189X),
RXRa (D-20, sc-553X), E4BP4 (V-19, sc-9549X), PDX1 (N-18, sc-
14662X), CEBPb (C-19, sc-150X), CUX1 (C-20, sc-6327X), and
p300 (C-20, sc-585X), Santa Cruz Biotechnology. Protein-DNA
complexes were separated by electrophoresis on 6% DNA retarda-
tion gels (Life Technologies) in 0.5 X TBE (Lonza), transferred to
nylon membranes (Thermo Scientific), and UV crosslinked before
chemiluminescent detection.Results
Fine Mapping of the 11q13.4 Locus, Associated with
Fasting Proinsulin and T2D
To finemap the association signal for fasting proinsulin, we
performed association analyses in 8,635 Finnish subjects
from the METSIM study with SNPs imputed from a refer-
ence panel of 2,737 sequenced central-northern European
individuals and SNPs directly genotyped on an exome
array.11 The lead SNP was rs7109575 (p ¼ 7.4 3 1050; n ¼
8,635), a noncoding variant located at the ARAP1 P2
TSS (Figure 1 and Table S4) and in high LD (r2 ¼ 0.94)
with previously reported lead proinsulin-associated SNP
rs1160333410 (p¼ 2.23 1048; n¼ 8,630). Conditional an-
alyses using rs11603334 or rs7109575 as covariates largely
attenuated the proinsulin association signal (all SNPs, p >
1.0 3 105; Figure 1, Figure S2, Table S4, and data not
shown). One rare missense variant genotyped in a 1 Mb
region on the exome array was associated (p < 0.05)
with proinsulin after conditional analysis (rs202137453,6, 2014
Figure 1. Variants Associatedwith Proin-
sulin in the METSIM Study
LocusZoom39 plots of fasting proinsulin
association adjusted for age, BMI, and fast-
ing insulin. The robust association with
proinsulin levels (top panel: rs7109575,
p ¼ 7.4 3 1050) is attenuated upon inclu-
sion of rs11603334 as a covariate (bottom
panel, only showing y axis to 1020).
Each SNP is colored according to its LD
(r2) with rs11603334. Genomic coordi-
nates refer to hg18 (UCSC Genome
Browser).MAF ¼ 0.003, p ¼ 0.015, pconditional rs11603334 ¼ 8.53 105,
Table S4). T2D association using 1,389 case and 5,748 con-
trol subjects (rs7109575, p ¼ 2.2 3 103; rs11603334, p ¼
3.6 3 103) was also attenuated after conditional analysis
(p > 0.05; Table S4, Figure S3, and data not shown). Taken
together, fine-mapping and conditional analyses provide
evidence supporting a functional role for common vari-
ant(s) in high LD with rs7109575 and rs11603334.
The Proinsulin-Decreasing and T2D-Risk Alleles Are
Associated with Increased ARAP1 mRNA Levels in
Primary Human Pancreatic Islets
To determine whether expression of ARAP1, STARD10,
PDE2A, or FCHSD2 is associated with the T2D- and fast-
ing-proinsulin-associated lead SNPs, we evaluated allelic
expression imbalance (AEI) in primary human pancreatic
islets. AEI maximizes sensitivity and power to detect
modest cis-acting effects on mRNA expression through
quantification of allele-specific transcript levels within
heterozygous samples, thereby controlling for differential
trans-acting and environmental exposures between indi-
viduals,40 as well as differential sample purity and viability
between islet preparations.41,42 The allelic composition of
the total transcript level for each gene was quantitatively
determined with Sequenom MALDI-TOF mass spectrom-
etry, a sensitive approach that conserves limited biological
sample, and statistically analyzed relative to the allelic
composition of the gDNA (Material andMethods). Located
in the first exon and 50 UTR of ARAP1 isoforms transcribedThe American Journal of Human Gefrom P1, previously reported lead
SNPs rs11603334 and rs1552224
demonstrated AEI (Figure 2). In
six samples heterozygous for
rs11603334 and rs1552224, we
observed ARAP1 expression differ-
ences of 7%–12% between alleles.
For both SNPs, the T2D-risk alleles
were associated with higher ARAP1
transcript levels (rs11603334, p ¼
0.0002; rs1552224, p ¼ 0.015).
Because of lower LD between the
lead SNPs and a third ARAP1 tran-
scribed SNP located in a downstreamexon, rs2291289 (r2 ¼ 0.12, D0 ¼ 1.0, rs11603334,
EUR), only three samples were heterozygous for both
rs2291289 and rs11603334 (Table 1). The gDNA-to-cDNA
comparison showed no AEI, whereas a comparison among
cDNA samples showed the nonrisk allele associated with
modestly increased transcript levels (Figure S4A). We also
attempted to evaluate AEI for nearby genes containing
transcribed SNPs in lower LD with rs11603334 by applying
previously described statistical methods.26 We did not
observe significant evidence of AEI for STARD10, PDE2A,
or FCHSD2 (Figures S4B–S4D and data not shown); zero
to four samples were heterozygous for each transcribed
SNP and rs11603334 (Table 1). Overall, these results sug-
gest that one or more functional variants in high LD
with rs11603334 and rs1552224 could increase the tran-
scriptional activity or message stability of ARAP1 isoforms
containing these SNPs.
Candidate Regulatory Variants at the ARAP1
Promoters
The originally identified lead SNPs rs11603334 and
rs1552224 at the P1 promoter overlap ENCODE tran-
scription factor binding sites within a region of open
and accessible chromatin that is marked by DNase hyper-
sensitivity and active histone H3 lysine modifications
H3K4me3 and H3K9ac in human pancreatic islets
(Figure 3 and Table S5). The lead fine-mapped SNP in
this study, rs7109575 (r2 ¼ 0.94 with rs11603334, EUR),
is located within a region of islet DNase hypersensitivitynetics 94, 186–197, February 6, 2014 189
Figure 2. The T2D-Risk Alleles of rs11603334 and rs1552224 Are
Associated with Increased ARAP1 Expression
Allelic expression analysis in human pancreatic islet gDNA and
cDNA from six donors each, including five matched pairs
(matched pairs only: rs11603334, p ¼ 0.0008; rs1552224, p ¼
0.06). The proportion of total gDNA and cDNA containing the
T2D-risk alleles of rs11603334 (left) and rs1552224 (right) from
heterozygous samples are quantified on the y axis. The cDNA con-
taining the T2D-risk allele was expressed 12.6% and 7.3% more
than the cDNA containing the nonrisk allele in the rs11603334
and rs1552224 assays, respectively. The p values were calculated
with a two-sided t test.and clustered transcription factor binding at the P2
promoter (Figure S5 and Table S5). Among the 17
additional variants in high LD with rs11603334 (r2 R
0.8, EUR; Table S5), rs77464186 (r2 ¼ 0.95 with
rs11603334, EUR) is the next most promising func-
tional candidate because of its location within a region
of islet DNase hypersensitivity and clustered transcrip-
tion factor binding in the first intron of ARAP1
isoforms transcribed from the P2 promoter (Figure S5
and Table S5).Table 1. Transcribed SNPs Used for Evaluating Allelic Expression Imba
Gene SNP Annotation Major/Minor Allele
ARAP1 rs11603334 50 UTR C/T
ARAP1 rs1552224 50 UTR T/G
ARAP1 rs2291289 synonymous A/G
STARD10 rs2291290 30 UTR A/G
STARD10 rs519790 50 UTR C/G
PDE2A rs392565 synonymous C/T
FCHSD2 rs76762469 30 UTR G/T
MAF, D0, and r2 data were estimated from 1000 Genomes Phase 1 populations o
disequilibrium; and MAF, minor allele frequency.
aOut of 87 total human pancreatic islet samples.
bThese D0 and r2 data were estimated from the 1000 Genomes Pilot CEU (Uta
collection) population.
190 The American Journal of Human Genetics 94, 186–197, FebruaryThe rs11603334 T2D-Risk and Proinsulin-Decreasing
Allele Increases Transcriptional Reporter Activity in
Rodent Pancreatic Beta Cell Lines
To interrogate allelic differences in transcriptional activity
of rs11603334, rs1552224, rs7109575, and rs77464186, we
cloned DNA sequences containing the T2D-risk (proinsu-
lin-decreasing) or nonrisk (proinsulin-increasing) alleles
into a promoterless luciferase vector and measured lucif-
erase activity in the MIN6 mouse and 832/13 rat beta cell
lines. Because of the perfect LD and short distance between
rs1552224 and rs11603334, we first tested them together
as a haplotype in the context of the ARAP1 P1 promoter.
A 1,357 bp region of DNA, defined byDNase hypersensitiv-
ity in human pancreatic islets and Pol2 binding in several
other cell types (Figure 3), exhibited strong transcriptional
activity in comparison to an empty vector control in both
MIN6 (Figure 4A) and 832/13 (Figure 4B). The rs1552224
and rs11603334 T2D-risk haplotype (TC) demonstrated a
2-fold increase in transcriptional activity in comparison
to the nonrisk haplotype (GT) in both MIN6 (p <
0.0001) and 832/13 (p ¼ 0.015), consistent with our
finding that the T2D-risk alleles are associated with
increased ARAP1 expression. The 1,357 bp region also con-
tained two short sequences of variable CT repeat length
(CT6–10); however, the numbers of repeats at the two sites
did not influence transcriptional activity (Figures S6A
and S6B). A narrower, 245 bp DNA region (Figure 3) con-
taining only variants rs1552224 and rs11603334 also
exhibited strong transcriptional activity in comparison
to an empty vector control (Figure 4C). As observed with
the 1,357 bp region, the two-SNP T2D-risk haplotype
(TC) demonstrated a 2-fold increase in transcriptional
activity in comparison to the nonrisk haplotype (GT)
(p ¼ 0.012). To determine which of the SNPs was respon-
sible for the haplotype effects on transcriptional activity
at the P1 promoter, we used site-directed mutagenesis to
synthetically create the alternate ‘‘missing’’ haplotypes.
Compared to the nonrisk T allele, the T2D-risk allele (C)lance for ARAP1, STARD10, PDE2A, and FCHSD2
MAF
LD with rs11603334
No. of Informative
HeterozygotesaD0 r2
0.16 1 1 6
0.16 1 1 6
0.41 0.94 0.12 3
0.11 1 0.025 2
0.28 0.97 0.071 2
0.30 0.011 0.0053 4
0.10 0.18b 0.001b 0
f European ancestry (EUR). The following abbreviations are used: LD, linkage
h residents with ancestry from northern and western Europe from the CEPH
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Figure 3. SNPs rs11603334 and rs1552224 Are Located in a Region with Evidence of Regulatory Potential at the ARAP1 P1 Promoter
at 72.11 Mb
UCSC Genome Browser (hg18) diagram showing rs11603334 and rs1552224 situated at the ARAP1 P1 promoter and 18 additional
variants in high LD (r2 R 0.8). ARAP1 is transcribed from right to left. SNPs rs11603334 and rs1552224 overlap regions of accessible
chromatin in human pancreatic islets detected by H3K4me3 and H3K9ac ChIP-seq, are situated within or proximal to regions of
open chromatin in human pancreatic islets detected by DNase hypersensitivity and FAIRE, and overlap binding sites for Pol2 and other
transcription factors detected by ChIP-seq in several ENCODE cell lines (see also Table S5). The DNA sequences cloned for evaluating
differential allelic transcriptional activity in the dual-luciferase reporter assays are indicated.of rs11603334 replicated the previously observed 2-fold
increase in transcriptional activity (p < 0.0001), whereas
the T2D-risk and nonrisk alleles of rs1552224 (T/G)
showed no significant difference (Figure 4D). We did not
observe evidence of allelic differences in transcriptional
activity for either rs7109575 (Figure 4E) or rs77464186
(Figure S6C) near the P2 promoter. However, compared
to the empty control vector, the 287 bp region of DNA
surrounding rs7109575 increased transcriptional activity
9-fold (p < 0.0001), consistent with promoter activity.
Decreased In Vitro Binding of PAX6 and PAX4 to the
rs11603334 T2D-Risk and Proinsulin-Decreasing
Allele
We performed EMSAs by using nuclear protein lysates
extracted from MIN6 and 832/13 cell lines to evaluate
differences in transcription factor binding to alleles of
rs11603334 and rs1552224. Multiple protein-DNA com-
plexes were observed in the EMSAs, consistent with expec-
tations for DNA within a promoter region (Figure 5 and
Figure S7). At least one protein complex was observed to
bind specifically to the nonrisk (T) allele of rs11603334
in MIN6 (Figure 5A, arrow). DNA competition assays using
excess unlabeled oligonucleotide containing the T allele
reproducibly disrupted the protein-DNA complex more
efficiently than did excess unlabeled oligonucleotide con-
taining the C allele, further supporting allelic differences
in protein binding (Figure 5A, lane 8 versus lane 9;The AmericFigure S7A, lane 7 versus lane 8). Preferential protein bind-
ing to the Tallele was also detected in 832/13 for a complex
with similar mobility (Figure S7A, lane 10, arrow). To
identify the differentially bound protein(s), we performed
EMSAs with supershift by using antibodies targeting
transcription factors selected from those with computa-
tionally predicted or empirically determined (ChIP-seq)
binding at rs11603334 (Material and Methods). Incuba-
tion with antibody targeting PAX6 partially disrupted the
T-allele-specific protein-DNA complex (Figure 5A, lane
10; Figure 5B, lane 8), and incubation with antibodies tar-
geting both PAX6 and PAX4 fully disrupted the complex
(Figure 5B, lane 10). Among the other transcription factors
tested with supershift assay, only AP-2b, HIF1a, and HIF1b
were observed to bind to the 21 bp DNA sequence contain-
ing rs11603334; these proteins bound to both the C and
T alleles with approximately equal affinity (Figures S7B
and S7C, arrows). We did not observe clear evidence of
allele-specific protein binding to rs1552224 (Figure S7D).Discussion
For most T2D-associated loci identified through GWASs,
the functional variants and affected genes are not known.
In this study, we have identified a plausible functional reg-
ulatory variant, rs11603334, and demonstrated its allelic
effects on expression of ARAP1, a gene at the 11q13.4an Journal of Human Genetics 94, 186–197, February 6, 2014 191
Figure 4. The T2D-Risk Allele, C, of
rs11603334 Increases Transcriptional
Activity of the ARAP1 P1 Promoter
Transcriptional activity was evaluated with
dual-luciferase reporter assays in the MIN6
mouse and 832/13 rat insulinoma b-cell
lines 48 hr after transfection with recombi-
nant vector containing selected regions
of the human ARAP1 promoters cloned
upstream of the luciferase gene.
(A) rs1552224 and rs11603334 evaluated
as a haplotype in a 1,357 bp region at the
ARAP1 P1 promoter in MIN6.
(B) rs1552224 and rs11603334 evaluated
as a haplotype in the 1,357 bp region in
832/13.
(C) rs1552224 and rs11603334 evaluated
as a haplotype in a narrower 245 bp region
at the ARAP1 P1 promoter in 832/13.
(D) Site-directed mutagenesis separated
the effects of rs1552224 and rs11603334
in the 245 bp region in 832/13.
(E) rs7109575 evaluated in a 287 bp region
at the ARAP1 P2 promoter in 832/13.
The p values were calculated with a two-
sided t test (A–C and E) or two-way
ANOVA (D). Data represent the mean of
two to ten clones per allele5 SD. A signif-
icance threshold of p < 0.05 was used. NS,
not significant.locus. We provide evidence suggesting that the C allele of
rs11603334 disrupts binding of transcriptional regulators
and increases transcriptional activity at the ARAP1 P1 pro-
moter and thus leads to higher ARAP1 expression in
pancreatic islets. Increased ARAP1 expression might be
one molecular genetic contributor to T2D susceptibility.
We conducted association analyses by using the densest
set of variants to date and report rs7109575 as the lead
fine-mapped SNP, confirming the primary robust associa-
tion between fasting proinsulin and previously reported
lead SNPs rs11603334 and rs1552224. Although not the
most strongly associated SNP in this study, our proposed
functional SNP (rs11603334) had an association p value
(p ¼ 2.2 3 1048) similar to that of rs7109575 (p ¼ 7.4 3
1050); sampling variability, missing genotypes, or imputa-
tion uncertaintymight influence the relative p values. Con-
ditioningoneither rs11603334or rs7109575attenuated the
proinsulin association, consistentwith a single signal at this
locus and supporting the use of the r2 measure of LD for
identifying candidate functional SNPs. Rare variants might
also contribute to variation in proinsulin levels among car-
riers. The variant that becamemore significant after adjust-
ment for rs11603334 (rs202137453, STARD10 c.586C>T
[p.Pro196Ser]) might be a true signal or a false positive
among 3,818 variants tested in this region. Further fine-
mapping and conditional analyses using a larger T2D case-
control population will be needed for determiningwhether
other variants in the region also contribute to T2D risk.
We have demonstrated that the T2D-risk alleles of
rs11603334 and rs1552224 are associated with increased
ARAP1 mRNA expression in primary human pancreatic
islets. This finding was reproducibly evident with a small192 The American Journal of Human Genetics 94, 186–197, Februarynumber of samples because AEI compares quantification
of allele-specific mRNA levels within heterozygous individ-
uals and thereby minimizes confounding effects, such as
interindividual environmental exposures, that can mask
genotypic effects in studies of expression quantitative trait
loci (eQTLs). We had the best power to detect association
between ARAP1 mRNA expression and rs11603334 and
rs1552224 because the SNPs are located within an exon;
this exon is specific to ARAP1 isoforms transcribed from
the P1 promoter. Previously, rs519790 was reported to be a
strong eQTL for STARD10 in blood (p¼ 2.73 1024);1 how-
ever, this SNP is in lowLDwith rs1552224 (r2¼ 0.071, EUR),
which shows only amodest, residual eQTL associationwith
STARD10 (blood, p ¼ 8.6 3 107; liver, p ¼ 1.79 3 105;
omental adipose tissue, p¼ 1.213 106).43 A nominal asso-
ciation between rs1552224 and ARAP1 (CENTD2) expres-
sion has been previously reported in T cells (p ¼ 0.019) in
a direction consistent with our results.44,45
In agreement with our finding that the T2D-risk alleles
of rs11603334 and rs1552224 are associated with increased
ARAP1 expression, our experiments using the tran-
scriptional reporter assay showed that the T2D-risk allele
of rs11603334 upregulates transcriptional activity at the
ARAP1 P1 promoter. Although transcriptional activity at
a gene promoter might be expected, allelic differences in
promoter activity cannot be predicted easily; functional as-
says are necessary for demonstrating allelic effects. Among
three tested variants situated at the ARAP1 P1 and P2 pro-
moters in this study, only rs11603334 demonstrated allelic
effects on promoter activity. Taken together, the results
from the AEI and transcriptional reporter assays implicate
increased expression of ARAP1 isoforms containing6, 2014
Figure 5. The T2D-Risk Allele, C, of
rs11603334 Disrupts Binding of Transcrip-
tional Regulators PAX6 and PAX4
Differential allelic protein-DNA binding
was evaluated in vitro with EMSAs.
Biotin-labeled 21 bp double-stranded
DNA oligonucleotide centered on the
reference (C) and alternate (T) alleles of
rs11603334 was incubated with MIN6
nuclear lysate, and resulting protein-DNA
complexes were separated by electropho-
resis (A and B: lanes 2 and 7, respectively).
For the competition assays, EMSA reac-
tions were incubated with 60-fold excess
unlabeled DNA oligonucleotide contain-
ing either the T or C allele (A: lanes 8 and
9, respectively). For the supershift assays,
EMSA reactions were incubated with
antibody targeting PAX6 (A: lane 10; B:
lane 8), PAX4 (B: lane 9), or both PAX6
and PAX4 (B: lane 10).rs11603334 and transcribed from the P1 promoter (RefSeq
accession numbers NM_015242.4 and NM_001135190.1)
in T2D susceptibility.
We have shown that the beta cell transcriptional regu-
lator PAX6 preferentially binds to the mRNA-lowering
allele (T) of rs11603334 in a protein-DNA complex that
could also contain PAX4, suggesting a repressive role for
one or both factors in transcription at the ARAP1 P1 pro-
moter (Figure 6). PAX6 and PAX4 have similar binding
sequences, although they bind DNAwith different relative
affinities.46–48 In the endocrine pancreas, PAX6 is often
reported to function as a transcriptional activator, whereas
PAX4 often functions as a repressor. PAX4 has been shown
to inhibit the transcriptional activity of coexpressed PAX6
in the HIT-T15 hamster beta cell line and in 293T cells,
possibly through competition for DNA binding sites.47
PAX4 also represses basal transcriptional activity of the
glucagon promoter in aTC1.9 and InR1G9 cells and
strongly represses PAX6-activated transcription of both
the glucagon48 and insulin promoters.49 However, repres-
sive activity for human and mouse PAX6 has also been
demonstrated for specific regulatory elements in other
cell types.50–52 The observed inhibition of transcrip-
tional activity for ARAP1 transcripts containing the
rs11603334 T allele might be mediated by PAX4, PAX6,
or both. Human coding variants in PAX4 or PAX6
have been previously implicated in impaired glucose
tolerance,53,54 early-onset diabetes,53,55 ketosis-prone dia-
betes,56 and proinsulin processing.57 Recently, genome-
wide association signals for T2D have also been identified
near PAX4 in East Asian2 and Chinese populations.58
Our results do not preclude the existence of additional
functional genes, variants, and/or mechanisms at this
locus. Power to detect association between the lead SNPs
and expression levels of STARD10, PDE2A, and FCHSD2
was limited as a result of small numbers of SNPs and
samples informative for AEI. Although 87 total islet
samples were available, only six were heterozygous for
rs11603334 and zero to four samples were informativeThe Americfor the STARD10, PDE2A, and FCHSD2 assays. We cannot
exclude possible associations between rs11603334 and
expression levels of these genes. An assay to test AEI for
all isoforms of ARAP1 (with the use of rs2291289) similarly
was of limited utility because of the small number of het-
erozygous samples (n ¼ 3) for this SNP and wide assay
variance. Moreover, ATG16L2 could not be tested with
this approach because it does not contain any common
transcribed SNPs. Future analysis of a larger pancreatic islet
expression data set will be required for validating our find-
ings for ARAP1 and assessing allelic differences in gene
expression for all other genes.
We chose to investigate the mechanisms underlying the
set of variants most strongly associated with proinsulin
and T2D after dense fine-mapping analyses. We prioritized
among highly significant noncoding variants on the
basis of their locations within regions of open chromatin
in pancreatic islets and successfully identified a variant
with allelic differences in transcriptional activity. Variants
located outside of these open chromatin regions might
also be found to have regulatory function. In addition,
functional noncoding variants at this locus might regulate
gene expression through allelic effects on splicing,
message stability, or translational control. On the basis
of sequence, rs1552224 creates a possible splice site, and
the rs11603334 T allele creates a methionine codon up-
stream of the RefSeq start codon. If used, this codon could
potentially lead to attempted translation of a 90 nt up-
stream open reading frame, which could interfere with effi-
cient translation of ARAP1.59
Specific roles for ARAP1 in the process of proinsulin con-
version and/or insulin secretion in the beta cell have not
yet been reported. ARAP1 is located near both the Golgi
and the plasma membrane in other cell types16,60–62 and
has been demonstrated to regulate several members of
the Arf and Rho small GTPase protein families in vitro
and in cell culture.16,63 Of the reported substrates, both
ARF6 and CDC42 have been shown to play a role in
glucose-stimulated insulin secretion.64–66 Future workan Journal of Human Genetics 94, 186–197, February 6, 2014 193
Figure 6. Proposed Model for PAX6 and PAX4 Repression of
Transcriptional Activity at ARAP1
PAX6 and PAX4 at rs11603334 in a complex with stronger binding
to the ARAP1 mRNA-decreasing T allele (B, T2D nonrisk) than to
the mRNA-increasing C allele (A, T2D risk) suggests a role for
one or both of these factors in repressing transcription at the
ARAP1 P1 promoter. Transcription factors HIF1a, HIF1b, and AP-
2b bind both alleles.will address the effects of upregulated ARAP1 expression
on proinsulin processing and insulin secretion in the
pancreatic beta cell. Given that our data suggest that
increased ARAP1 expression is associated with increased
risk of T2D, ARAP1 antagonists might hold important ther-
apeutic potential.
Identifying functional variants at T2D GWAS loci and
elucidating mechanisms to explain how variants influence
expression or function of target genes will help facilitate
the discovery of biological gene candidates and novel
pathways involved in disease pathology. This work con-
tributes to a growing understanding of the molecular
genetic architecture of T2D, provides a model of fine-
mapping and experimental analyses that can be used for
uncovering functional variants contributing to associa-
tions at GWAS loci, and paves the way for future research
on the role of ARAP1 as a diabetes candidate gene in
pancreatic islets.Supplemental Data
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